AU2008313622A1 - Solid dispersion product of N-aryl urea-based drugs - Google Patents

Solid dispersion product of N-aryl urea-based drugs Download PDF

Info

Publication number: AU2008313622A1
Authority: AU; Australia
Prior art keywords: group; phenyl; amino; alkyl; urea
Prior art date: 2007-10-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2008313622A

Other languages

English (en)

Inventor

Tanja Heitermann

Rudolf Schroeder

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott GmbH and Co KG

Original Assignee

Abbott GmbH and Co KG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-19

Filing date

2008-10-17

Publication date

2009-04-23

2008-10-17 Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG

2009-04-23 Publication of AU2008313622A1 publication Critical patent/AU2008313622A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU2008313622A 2007-10-19 2008-10-17 Solid dispersion product of N-aryl urea-based drugs Abandoned AU2008313622A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US99961807P	2007-10-19	2007-10-19
US60/999,618		2007-10-19
PCT/EP2008/064076 WO2009050291A2 (en)	2007-10-19	2008-10-17	Solid dispersion product of n-aryl urea-based drugs

Publications (1)

Publication Number	Publication Date
AU2008313622A1 true AU2008313622A1 (en)	2009-04-23

Family

ID=40089463

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2008313622A Abandoned AU2008313622A1 (en)	2007-10-19	2008-10-17	Solid dispersion product of N-aryl urea-based drugs

Country Status (18)

Country	Link
EP (1)	EP2197425A2 (es)
JP (1)	JP2011500649A (es)
KR (1)	KR20100087170A (es)
CN (1)	CN101827584A (es)
AU (1)	AU2008313622A1 (es)
BR (1)	BRPI0818340A2 (es)
CA (1)	CA2699301A1 (es)
CO (1)	CO6270206A2 (es)
CR (1)	CR11442A (es)
DO (1)	DOP2010000117A (es)
EC (1)	ECSP10010183A (es)
GT (1)	GT201000102A (es)
MX (1)	MX2010004291A (es)
PA (1)	PA8800101A1 (es)
RU (1)	RU2010119929A (es)
UA (1)	UA100865C2 (es)
WO (1)	WO2009050291A2 (es)
ZA (1)	ZA201002095B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009100176A2 (en) *	2008-02-07	2009-08-13	Abbott Laboratories	Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
AR077975A1 (es)	2009-08-28	2011-10-05	Irm Llc	Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
TW201202234A (en) *	2010-06-09	2012-01-16	Abbott Lab	Solid dispersions containing kinase inhibitors
CN108542906A (zh)	2011-11-11	2018-09-18	诺华股份有限公司	治疗增生性疾病的方法
EP3449911A1 (en)	2011-11-23	2019-03-06	Array Biopharma, Inc.	Pharmaceutical formulations
WO2014003677A1 (en) *	2012-06-28	2014-01-03	Xspray Microparticles Ab	Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) *	2012-06-28	2014-01-03	Xspray Microparticles Ab	Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2016198983A1 (en)	2015-06-09	2016-12-15	Bend Research Inc.	Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1959926A1 (en) *	2005-10-25	2008-08-27	Abbott Laboratories	Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) *	2005-12-09	2007-06-14	Pfizer Products Inc.	Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) *	2006-11-09	2008-05-15	Abbott Gmbh & Co. Kg	Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

2008
- 2008-10-17 CA CA2699301A patent/CA2699301A1/en not_active Abandoned
- 2008-10-17 JP JP2010529408A patent/JP2011500649A/ja active Pending
- 2008-10-17 CN CN200880112150A patent/CN101827584A/zh active Pending
- 2008-10-17 UA UAA201006029A patent/UA100865C2/ru unknown
- 2008-10-17 AU AU2008313622A patent/AU2008313622A1/en not_active Abandoned
- 2008-10-17 EP EP08839333A patent/EP2197425A2/en not_active Withdrawn
- 2008-10-17 WO PCT/EP2008/064076 patent/WO2009050291A2/en active Application Filing
- 2008-10-17 PA PA20088800101A patent/PA8800101A1/es unknown
- 2008-10-17 KR KR1020107010979A patent/KR20100087170A/ko not_active Application Discontinuation
- 2008-10-17 MX MX2010004291A patent/MX2010004291A/es not_active Application Discontinuation
- 2008-10-17 BR BRPI0818340 patent/BRPI0818340A2/pt not_active IP Right Cessation
- 2008-10-17 RU RU2010119929/15A patent/RU2010119929A/ru not_active Application Discontinuation
2010
- 2010-03-24 ZA ZA2010/02095A patent/ZA201002095B/en unknown
- 2010-04-16 DO DO2010000117A patent/DOP2010000117A/es unknown
- 2010-04-16 GT GT201000102A patent/GT201000102A/es unknown
- 2010-04-27 CO CO10049271A patent/CO6270206A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010183A patent/ECSP10010183A/es unknown
- 2010-05-19 CR CR11442A patent/CR11442A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2009050291A3 (en)	2010-04-08
CN101827584A (zh)	2010-09-08
DOP2010000117A (es)	2010-05-15
ZA201002095B (en)	2011-11-30
KR20100087170A (ko)	2010-08-03
BRPI0818340A2 (pt)	2015-04-22
MX2010004291A (es)	2010-08-02
GT201000102A (es)	2012-03-12
WO2009050291A2 (en)	2009-04-23
RU2010119929A (ru)	2011-11-27
ECSP10010183A (es)	2010-06-29
PA8800101A1 (es)	2009-05-15
CA2699301A1 (en)	2009-04-23
JP2011500649A (ja)	2011-01-06
EP2197425A2 (en)	2010-06-23
CO6270206A2 (es)	2011-04-20
CR11442A (es)	2010-09-06
UA100865C2 (ru)	2013-02-11

Similar Documents

Publication	Publication Date	Title
AU2008313622A1 (en)	2009-04-23	Solid dispersion product of N-aryl urea-based drugs
RU2728824C1 (ru)	2020-07-31	Препарат активатора глюкокиназы для перорального введения и способ его получения
US20090143423A1 (en)	2009-06-04	Solid dispersion product containing n-aryl urea-based compound
BR112020024107A2 (pt)	2021-02-17	combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos
US10493161B2 (en)	2019-12-03	Solution for spray drying comprising hypromellose acetate succinate and method for producing solid dispersion
BRPI0715712B1 (pt)	2021-03-23	Composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina
KR20120109522A (ko)	2012-10-08	시그마 수용체 리간드들을 포함하는 약학 조성물들
JP2003503380A (ja)	2003-01-28	無定形硝酸エステルおよびその製剤組成物
WO2002040054A1 (fr)	2002-05-23	Preparation pharmaceutique contenant de la copolyvidone
TW202216117A (zh)	2022-05-01	經口用醫藥組成物及其製造方法
JP2001511796A (ja)	2001-08-14	環状四級アンモニウム化合物を経口投与するための乾燥形態の薬学的調合剤
JP2003527424A (ja)	2003-09-16	オキサゾリジノン錠剤製剤
CN109010837B (zh)	2021-09-28	一种具有高溶解性的塞来昔布组合物
KR100912196B1 (ko)	2009-08-14	Ｌｔｂ4 길항제를 함유하는 약제학적 제형
JP2002212063A (ja)	2002-07-31	コポリビドン含有製剤
EP4076407B1 (en)	2023-08-23	A pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix
RU2826604C1 (ru)	2024-09-13	Фармацевтическая композиция соединения пиразола, диспергированного в матрице полимера
JP5106119B2 (ja)	2012-12-26	シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
CA3232832A1 (en)	2023-03-30	Pharmaceutical composition and a process to prepare the same
JP2024091760A (ja)	2024-07-05	非晶質固体分散体を含む複合物
RU2261095C1 (ru)	2005-09-27	Лекарственная форма, обладающая нестероидным противовоспалительным действием, и способ ее изготовления
WO2021006267A1 (ja)	2021-01-14	ピラゾール誘導体の塩及びピラゾール誘導体の製剤
CN106456612A (zh)	2017-02-22	经口给药用医药组合物
TR2022013345A2 (tr)	2024-03-21	Si̇nnari̇zi̇n ve di̇menhi̇dri̇nat kombi̇nasyonu i̇çeren farmasöti̇k kompozi̇syon
JPWO2020246526A1 (ja)	2021-09-13	キサンチンオキシダーゼ阻害剤含有腸溶性製剤

Legal Events

Date	Code	Title	Description
2014-05-15	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application